Advancing CML Management Towards an Ideal Patient Journey

Opinion
Video

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following:

  • What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
  • What excites you most about the potential advancements in CML management that may be on the horizon in the next 5 to 10 years?
  • How do you envision the CML patient experience being transformed compared to today? What would an "ideal" CML journey look like for patients and their loved ones? What would be your top recommendations if you were to advise the broader healthcare system on how to better support CML patients and caregivers?
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.